FDA Guidelines on Control of Nitrosamine Impurities

In September 2024, the U.S. Food and Drug Administration (FDA) released a revised version of the guidelines for controlling nitrosamine impurities in human drugs. This is an important directive for regulators and drug manufacturers. The guidelines provide a comprehensive framework for the detection, prevention, and control of nitrosamine impurities in active pharmaceutical ingredients (APIs) and drug products.

Understanding the Risks

Nitrosamines are a class of compounds that may pose significant health risks to humans. During pharmaceutical production, amines (organic compounds derived from ammonia) can react with nitrosating agents, such as nitrites, under certain conditions (e.g., acidic environments) to form nitrosamines, such as N-nitrosodimethylamine (NDMA). The International Agency for Research on Cancer (IARC) classifies NDMA as a probable human carcinogen based on evidence from animal studies. Nitrosamines can be generated at various stages of drug production and may be introduced during storage or through contamination of raw materials. The discovery of nitrosamines in some widely used medications, such as angiotensin II receptor blockers (ARBs), in 2018 raised concerns among regulatory agencies.

The revised FDA guidelines aim to address these issues by establishing clearer requirements and procedures for manufacturers to identify, assess, and control the presence of nitrosamine impurities in their products. Although the guidelines primarily apply to small molecule drugs, such as chemically synthesized APIs and drug products, they also extend to biological products and other high-risk products that involve synthetic operations.

Causes of Formation

One of the core objectives of the guidelines is to identify the root causes of nitrosamine impurities so that manufacturers can adopt more effective control strategies. Various factors can lead to the formation of nitrosamines in drugs, and these factors vary depending on the materials and processes used during production. Below are some major sources identified by the FDA:

1. Use of Amines in Synthesis: Nitrosamines are typically formed when secondary, tertiary, or quaternary amines react with nitrosating agents such as nitrites. Drug products and APIs containing amine reagents are particularly susceptible to this reaction under acidic conditions. The presence of amines in reagents, solvents, or catalysts during production can trigger this reaction. For example, the use of nitrites to neutralize residual azides in certain chemical syntheses can create favorable conditions for nitrosamine formation.
2. Recycling of Solvents, Reagents, and Catalysts: Another major source of nitrosamine contamination is the use of recycled solvents, reagents, and catalysts that have not been adequately purified. During recycling, residual amines may remain in the solvent and react with nitrites in subsequent steps of the production process. Without proper monitoring and purification, these nitrosamines can be introduced into the final drug product, even if the drug product itself does not involve high-risk processes.
3. Quality and Consistency of Raw Materials: The quality and consistency of raw materials used in drug production play a crucial role in controlling nitrosamine impurities. Raw materials supplied by vendors may contain trace amounts of nitrosamines or their precursors (e.g., secondary or tertiary amines). In some cases, impurities may be introduced during the storage or transportation of raw materials, especially when solvents or chemicals are reused without adequate cleaning. Cross-contamination is another risk when handling raw materials in facilities that process nitrosamine-containing substances.
4. Inadequate Process Controls: If the production process is not properly optimized or controlled, the process itself can lead to the formation of nitrosamines. Variations in reaction conditions, such as temperature, pH, and the order of reagent addition, can result in nitrosamine formation. Additionally, poorly controlled purification steps may fail to effectively remove these impurities. For instance, certain drying processes (e.g., high-temperature fluid bed drying) can promote the formation of nitrosamines in APIs containing nitrogen groups.
5. Excipients and Packaging Materials: In addition to raw materials and synthesis processes, nitrosamine impurities may also originate from excipients used in drug formulations and packaging materials. Nitrites, as common nitrosating agents, are often present in excipients such as preservatives, stabilizers, and fillers. These impurities can react with amines in the API, leading to nitrosamine formation during the shelf life of the drug. Similarly, certain types of packaging materials may introduce nitrosamines into the drug through leaching or contamination.

Control Strategies

The FDA guidelines outline a three-step strategy to reduce the risk of nitrosamine contamination in APIs and drug products. This structured approach can help manufacturers prioritize risk assessments, ensure thorough testing, and implement necessary process changes. The recommended steps are as follows:

1. Conduct Risk Assessments: The first step in reducing nitrosamine impurities is to conduct comprehensive risk assessments. Manufacturers must evaluate their APIs and drug products to identify potential sources of nitrosamine formation, including raw materials, excipients, synthetic processes, and storage conditions. Risk assessments should prioritize high-risk products based on factors such as the maximum daily dose, duration of treatment, and patient population.
2. Perform Confirmatory Testing: Once risks are identified, manufacturers must conduct confirmatory testing to verify the presence and concentration of nitrosamine impurities in their products. Testing should use validated, high-sensitivity analytical methods capable of detecting trace amounts of nitrosamines. Chromatographic techniques, such as high-performance liquid chromatography (HPLC) coupled with mass spectrometry (MS), can typically provide high specificity and sensitivity.
3. Report and Implement Changes: If nitrosamine impurities are detected in an API or drug product, manufacturers must take immediate action to reduce the risk. This includes altering production processes, raw materials, or suppliers to minimize or eliminate nitrosamine formation. Any changes made to approved drug applications must be reported to the FDA in accordance with relevant regulations, such as 21 CFR 314.70 (for New Drug Applications (NDAs)) and 21 CFR 601.12 (for biological products).

Establishing Acceptable Intake Limits

A key part of the FDA guidelines is the establishment of acceptable intake (AI) limits for nitrosamine impurities. These limits aim to minimize the risk of carcinogenicity from long-term exposure to nitrosamines in drugs. Based on a lifetime exposure (70 years), AI limits are typically set at levels corresponding to an extra cancer risk of one case per 100,000 people.

For most nitrosamine impurities, the FDA has established specific AI limits based on toxicological data. However, for some nitrosamines lacking data, manufacturers are advised to follow the recommendations outlined in the International Council for Harmonisation (ICH) guideline M7(R2), which sets a general threshold of 1.5 micrograms per day for toxicological concern. If a drug contains multiple nitrosamines, manufacturers must ensure that the total content of nitrosamines does not exceed the AI limit for the most potent carcinogenic impurity. In some cases, a flexible approach may be required, especially when the AI limits for individual nitrosamines vary widely.

In addition to the three-step mitigation strategy, the FDA guidelines also outline several preventive and control measures that manufacturers can implement to reduce the risk of nitrosamine contamination. These include:

1. Process Optimization: Manufacturers should optimize their API synthesis processes to avoid conditions that may lead to nitrosamine formation. This includes selecting appropriate reagents and solvents, controlling reaction conditions such as temperature and pH, and implementing effective purification steps to remove nitrosamine precursors. Whenever possible, alternative quenching agents should be used instead of nitrites to minimize the risk of nitrosamine formation during chemical reactions.
2. Supplier Qualification and Raw Material Control: Ensuring the quality and consistency of raw materials is critical to controlling nitrosamine impurities. Manufacturers must implement robust supplier qualification programs to assess the contamination risks of raw materials from suppliers. This may involve setting additional quality standards for raw materials, auditing suppliers, and conducting regular testing to monitor nitrosamines or their precursors.
3. Control of Recycled Materials: When using recycled solvents, reagents, or catalysts in production, manufacturers must ensure that these materials are adequately purified to remove residual nitrosamines. The FDA recommends using recycled materials only within the same process step to prevent cross-contamination. If recycling is performed by third-party contractors, manufacturers should audit the facilities used to verify their cleaning procedures and ensure compliance with good manufacturing practices.
4. Monitoring of Excipients and Packaging Materials: Excipients used in drug formulations must be carefully selected and monitored for nitrosamine impurities, as nitrites can react with the API to form nitrosamines. Manufacturers should implement excipient supplier qualification programs and conduct regular testing to ensure nitrite levels remain within acceptable limits. Packaging materials should also be assessed for their potential to introduce nitrosamines into drugs through leaching or contamination.
5. Handling of Nitrosamine Drug Substance-Related Impurities (NDSRIs): One of the important new additions to the FDA revised guidelines is the focus on NDSRIs. These nitrosamines are formed from the APIs themselves or their fragments during nitrosation that occurs in the production or storage processes. Controlling NDSRIs is particularly challenging as they are unique to each API and often lack comprehensive toxicological data. The FDA recommends that manufacturers take special precautions to prevent the formation of NDSRIs by screening for nitrite impurities in excipients, adding antioxidants to formulations, and adjusting the pH of the drug to neutral or alkaline levels. These strategies can significantly reduce the risk of NDSRI formation and ensure that they remain within acceptable safety limits throughout the drug's shelf life.

Conclusion

As the global pharmaceutical industry continues to evolve, manufacturers must remain vigilant in detecting, preventing, and controlling nitrosamine impurities in their products. By following the FDA's three-step mitigation strategy—conducting risk assessments, performing confirmatory testing, and implementing process changes—manufacturers can effectively minimize the risk of nitrosamine contamination. Additionally, adopting preventive measures such as process optimization, supplier qualification, and careful selection of excipients and packaging materials will help ensure compliance with regulatory requirements and protect public health.

Highlights

• The FDA released revised guidelines in September 2024 to control nitrosamine impurities in human drugs, providing a comprehensive framework for detection and prevention.
• Nitrosamines, including N-nitrosodimethylamine (NDMA), are classified as probable human carcinogens and can form during drug production processes.
• The guidelines identify key sources of nitrosamine formation, such as the use of amines, recycled materials, and inadequate process controls.
• A three-step control strategy includes conducting risk assessments, performing confirmatory testing, and reporting necessary changes to reduce nitrosamine contamination.
• The FDA established acceptable intake limits for nitrosamines, aiming to minimize carcinogenic risks associated with long-term exposure.
• Preventive measures outlined in the guidelines include process optimization, raw material control, and monitoring of excipients and packaging materials.
• The guidelines emphasize the control of nitrosamine drug substance-related impurities (NDSRIs), which are challenging to manage and require special precautions.